Antioxidants may shield kidneys from colistin damage in ICU patients
NCT ID NCT06650384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed trial tested whether two antioxidants, N-acetylcysteine and alpha-lipoic acid, could prevent kidney damage caused by the antibiotic colistin in 180 critically ill patients. Participants received either colistin alone or colistin plus one of the antioxidants. The study tracked kidney function daily to see if the antioxidants reduced the risk of acute kidney injury.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- N-acetylcysteine and alpha-lipoic acid
- What this could lead to
- If successful, this could point toward a simple way to protect kidneys in critically ill patients who need colistin, reducing the risk of kidney failure.
- What could go wrong
- This is a completed Phase 2/3 trial, but results are not yet widely confirmed. The benefit may be small or not apply to all patients, and antioxidants can have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTOXICITY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Critical Care Medicine Department,Cairo University Hospitals
Cairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.